Related Experiment Videos

Genetic polymorphisms in the CD40 ligand gene and Kawasaki disease

Fu-Yuan Huang1, Tzu-Yang Chang, Ming-Ren Chen

  • 1Department of Pediatrics, Mackay Memorial Hospital, 45, Min-Sheng Rd., Tamshui, 25115 Taipei, Taiwan.

Journal of Clinical Immunology
|May 16, 2008
PubMed

Insights

Genetic variations in the CD40 ligand (CD40L) gene were not linked to Kawasaki disease (KD) or coronary artery lesions (CAL) in Taiwanese children. Further research in diverse ethnic groups is needed to confirm these findings for KD susceptibility.

Area of Science:

  • Immunogenetics
  • Pediatric Infectious Diseases

Background:

  • Kawasaki disease (KD) is an enigmatic pediatric illness with suspected genetic and immunological underpinnings.
  • The precise etiological factors contributing to KD pathogenesis remain largely unknown.

Purpose of the Study:

  • To investigate the association between CD40 ligand (CD40L) gene polymorphisms and Kawasaki disease (KD).
  • To determine if CD40L gene variations are linked to the development of coronary artery lesions (CAL) in Taiwanese children.

Main Methods:

  • Genotyping of CD40L single nucleotide polymorphisms (SNPs), specifically -3459 A/G and IVS4+121 A/G.
  • Utilized TaqMan assay for SNP analysis in 167 KD patients and 1,010 healthy controls.
  • Performed haplotype analysis to further assess genetic associations.

Main Results:

  • No significant association was found between the studied CD40L polymorphisms and susceptibility to KD.
  • The investigated CD40L SNPs did not correlate with the development of coronary artery lesions (CAL) in KD patients.
  • Haplotype analysis corroborated the lack of association between CD40L variants and KD or CAL.

Conclusions:

  • The findings suggest that specific CD40L SNPs are unlikely to play a significant role in KD susceptibility or CAL development in Taiwanese children.
  • Further validation and replication studies in larger, independent ethnic cohorts are recommended to confirm these results.
  • This study contributes to understanding the genetic landscape of Kawasaki disease.
Abstract

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...